Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis

被引:2
|
作者
Karashima, Ryo [1 ,2 ,3 ]
Sagami, Shintaro [1 ,2 ]
Yamana, Yoko [1 ]
Maeda, Masa [1 ]
Hojo, Aya [1 ,2 ]
Miyatani, Yusuke [1 ]
Nakano, Masaru [1 ,2 ]
Matsuda, Takahisa [3 ]
Hibi, Toshifumi [1 ]
Kobayashi, Taku [1 ,2 ,4 ]
机构
[1] Kitasato Univ, Kitasato Inst Hosp, Ctr Adv IBD Res & Treatment, 5-9-1 Shirokane,Minato Ku, Tokyo 1088642, Japan
[2] Kitasato Univ, Kitasato Inst Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan
[3] Toho Univ, Omori Med Ctr, Div Gastroenterol & Hepatol, Tokyo, Japan
[4] Kitasato Univ, Sch Med, Dept Gastroenterol, Sagamihara, Japan
关键词
Leucine-rich alpha-2-glycoprotein; Inflammatory bowel disease; Ulcerative colitis; Biomarkers; C-REACTIVE PROTEIN; INFLAMMATORY-BOWEL-DISEASE; FECAL CALPROTECTIN; ALPHA-2; GLYCOPROTEIN; INTESTINAL INFLAMMATION; ACTIVITY BIOMARKER; ACTIVITY INDEXES; VARIABILITY; LACTOFERRIN; IMPROVEMENT;
D O I
10.5217/ir.2023.00135
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Leucine-rich alpha -2-glycoprotein (LRG) is a new serum biomarker reflecting the disease activity of ulcerative colitis (UC), but its change during the acute phase has not been enough investigated. Methods: Patients with UC who initiated the induction therapy with steroid or advanced therapy (biologics or Janus kinase inhibitors) were prospectively enrolled. Associations of LRG, C -reactive protein (CRP) and fecal calprotectin (FC) at baseline, week 1, and week 8 with clinical remission at week 8 and subsequent endoscopic improvement within 1 year (Mayo endoscopic subscore of 0 or 1) were assessed. Results: A total of 143 patients with UC were included. LRG and CRP at week 1 were significantly lower in the clinical remission group than in the non -remission group (LRG, 20.6 mu g/mL vs. 28.4 mu g/mL, P < 0.001; CRP, 0.9 mg/dL vs. 2.3 mg/dL, P < 0.001) while FC demonstrated the difference between groups only at week 8. The area under the curves of week 1 LRG, CRP, and FC for week 8 clinical remission using the receiver operating characteristic curves analysis were 0.68, 0.71, and 0.57, respectively. Furthermore, LRG and CRP predicted subsequent endoscopic improvement as early as week 1, while FC was predictive only at week 8. Conclusions: LRG can be an early -phase biomarker predicting subsequent clinical and endoscopic response to induction therapy.
引用
收藏
页码:473 / 483
页数:11
相关论文
共 50 条
  • [41] A novel phospholipase A2 inhibitor with leucine-rich repeats from the blood plasma of Agkistrodon blomhoffii siniticus -: Sequence homologies with human leucine-rich α2-glycoprotein
    Okumura, K
    Ohkura, N
    Inoue, S
    Ikeda, K
    Hayashi, K
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (31) : 19469 - 19475
  • [42] Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn's disease
    Abe, Izuru
    Shiga, Hisashi
    Chiba, Hirofumi
    Miyazawa, Teruko
    Oomori, Shinya
    Shimoyama, Yusuke
    Moroi, Rintaro
    Kuroha, Masatake
    Kakuta, Yoichi
    Kinouchi, Yoshitaka
    Masamune, Atsushi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (09) : 1741 - 1748
  • [43] Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease
    Shimoyama, Takahiro
    Yamamoto, Takayuki
    Yoshiyama, Shigeyuki
    Nishikawa, Ryutaro
    Umegae, Satoru
    INFLAMMATORY BOWEL DISEASES, 2022, : 1399 - 1408
  • [44] Proteomic Analysis of Coronary Sinus Serum Reveals Leucine-Rich α2-Glycoprotein as a Novel Biomarker of Ventricular Dysfunction and Heart Failure
    Watson, Chris J.
    Ledwidge, Mark T.
    Phelan, Dermot
    Collier, Patrick
    Byrne, Jennifer C.
    Dunn, Michael J.
    McDonald, Kenneth M.
    Baugh, John A.
    CIRCULATION-HEART FAILURE, 2011, 4 (02) : 188 - U126
  • [45] Leucine-rich alpha 2 glycoprotein reduces the necessity for endoscopic examination for activity evaluation
    Hayasix, T. Hayashi
    Takatori, H.
    Yamashita, T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 449 - 449
  • [46] Serum leucine-rich α2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Still's disease
    Ha, Y-J
    Kang, E-J
    Lee, S-W
    Park, Y-B
    Lee, S-K
    Song, J-S
    Choi, S. T.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2015, 44 (05) : 399 - 403
  • [47] Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn's Disease
    Kawamura, Tatsuya
    Yamamura, Takeshi
    Nakamura, Masanao
    Maeda, Keiko
    Sawada, Tsunaki
    Ishikawa, Eri
    Iida, Tadashi
    Mizutani, Yasuyuki
    Ishikawa, Takuya
    Kakushima, Naomi
    Furukawa, Kazuhiro
    Ohno, Eizaburo
    Honda, Takashi
    Kawashima, Hiroki
    Ishigami, Masatoshi
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (02) : 245 - 253
  • [48] Clinical Profiles of Leucine-Rich Alpha-2 Glycoprotein for Indicating Mucosal Healing in Ulcerative Colitis Patients under Administration of Molecular-Targeted Drug
    Matsumoto, Satohiro
    Mashima, Hirosato
    DIGESTIVE DISEASES, 2024,
  • [49] Leucine-rich α-2-glycoprotein 1 can be a novel angiogenic mediator in autosomal dominant polycystic kidney disease
    Erdogan, Hazal Fatma
    Ozcan, Oguzhan
    Dogan, Ibrahim
    Oguzman, Hamdi
    Turgut, Faruk Hilmi
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2025,
  • [50] Diagnostic Accuracy of Leucine-Rich α-2-Glycoprotein 1 as a Non-Invasive Salivary Biomarker in Pediatric Appendicitis
    Tintor, Goran
    Jukic, Miro
    Supe-Domic, Daniela
    Jeroncic, Ana
    Pogorelic, Zenon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)